Weiwei Dai is dedicated to supporting innovation in the biotechnology and life sciences sectors through strategic patent prosecution and comprehensive legal analysis. As a patent agent and law clerk in the firm’s Chemical, Biotechnology & Pharmaceutical Practice Group, Weiwei leverages a robust technical background in antibody technology, cell and gene therapies, and next-generation sequencing (NGS) to deliver impactful results for clients.

Weiwei’s practice focuses on drafting and prosecuting U.S. and international patent applications, managing global patent portfolios, and conducting thorough due diligence, freedom-to-operate, infringement, and validity analyses. Weiwei collaborates closely with inventors, scientists, and investors to translate cutting-edge research into patentable inventions and secure intellectual property rights.

Prior to joining Foley, Weiwei worked at an international law firm, where Weiwei managed patent portfolios, drafted and prosecuted patent applications in biotechnology and life sciences, and conducted IP diligence for major investment deals.

Weiwei has postdoctoral research experience at Howard Hughes Medical Institute and Johns Hopkins University, leading projects in antiviral immunity, HIV cure strategies, and COVID-19 research. She developed expertise in high-throughput screening, CRISPR functional genomics, and RNA sequencing, collaborating with interdisciplinary teams. Weiwei is currently a J.D. candidate at George Washington University Law School.